title: Chronic renal failure complications and management in kidney transplanted and nontransplanted patients.
abstract: BACKGROUND
  Our purpose was to compare the management of chronic kidney disease (CKD) according to Kidney Disease Quality Initiative (K/DOQI) recommendations in kidney transplanted patients (T) and nontransplanted ones (NT).
  
  
  METHODS
  Data concerning CKD complications were collected retrospectively. Patients seen in consultations in our department from May 2009 to June 2010 were selected if they had at least 6 months of follow-up, CKD stage 4 or 5, and no exclusion criteria namely hospitalization, active cancer, or infection in the 3 months before data collection.
  
  
  RESULTS
  Fifty-eight T were compared with 85 NT matched by CKD stage (4-5). Anemia within K/DOQI target was better controlled among NT (51.2% versus 41.3%); however, ferritin levels within K/DOQI target were higher (80% T versus 51.7% NT). Average arterial blood pressure was similar in both groups but 51.7% of T were in K/DOQI target versus 41% of NT. Dyslipidemia within cholesterol K/DOQI target was better controlled in 60% (NT) versus 35% NT with 63.5% versus 38% NT within low-density lipoprotein K/DOQI targets. Phosphorus level was better controlled among T; parathyroid was better controlled in among 65% NT versus 50% T within the target level.
  
  
  CONCLUSIONS
  Most complications of CKD were better managed among NT.
authors.affiliation: Department of Nephrology, University Hospital of Clermont-Ferrand, Clermont-Ferrand, France. salehkaysi@gmail.com
authors.forename: S
authors.initials: S
authors.lastname: Kaysi
authors.forename: M
authors.initials: M
authors.lastname: Hadj Abdelkader
authors.forename: J
authors.initials: J
authors.lastname: Aniort
authors.forename: C
authors.initials: C
authors.lastname: Garrouste
authors.forename: C
authors.initials: C
authors.lastname: Philipponnet
authors.forename: P
authors.initials: P
authors.lastname: Deteix
authors.forename: A Elizabeth
authors.initials: AE
authors.lastname: Heng
mesh_terms: D000740:Anemia / Q000097:blood / Q000209:etiology / Q000628:therapy; D015415:Biomarkers / Q000097:blood; D001794:Blood Pressure; D016009:Chi-Square Distribution; D050171:Dyslipidemias / Q000097:blood / Q000209:etiology / Q000628:therapy; D005293:Ferritins / Q000097:blood; D019983:Guideline Adherence; D006801:Humans; D006973:Hypertension / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications / Q000503:physiopathology / Q000601:surgery / Q000628:therapy*; D016030:Kidney Transplantation / Q000009:adverse effects / Q000592:standards; D008055:Lipids / Q000097:blood; D010043:Outcome and Process Assessment, Health Care / Q000592:standards; D010281:Parathyroid Hormone / Q000097:blood; D010758:Phosphorus / Q000097:blood; D017410:Practice Guidelines as Topic; D006435:Renal Dialysis / Q000009:adverse effects / Q000592:standards; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D008055:Lipids; C470125:PTH protein, human; D010281:Parathyroid Hormone; D010758:Phosphorus; D005293:Ferritins